The ILKAP Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung carcinoma epithelial cell line. This polyclonal population has undergone CRISPR/Cas9-mediated gene disruption targeting the ILKAP locus, resulting in a heterogeneous pool of cells with loss-of-function mutations in the ILKAP gene. As a polyclonal knockout model, it retains genetic diversity while collectively abrogating functional ILKAP expression, providing a robust tool for studying the phosphatase-dependent regulation of cellular processes. The product is supplied as a ready-to-use polyclonal knockout pool, suitable for immediate expansion and experimentation in biomedical research settings.
The host A-549 cell line is a widely utilized adherent epithelial model derived from the lung carcinoma tissue of a 58-year-old male. These cells exhibit characteristic epithelial morphology and serve as a well-established system for lung adenocarcinoma research, including studies of oncogenic signaling, drug response, and metastatic behavior. A-549 cells maintain key molecular features of lung adenocarcinoma, such as activating KRAS mutations and deregulated growth factor pathways, making them a physiologically relevant context for investigating genes implicated in tumor progression. Their robust growth and reproducible experimental properties further enhance their utility as a knockout host.
ILKAP encodes a member of the protein phosphatase 2C (PP2C) family that specifically interacts with and dephosphorylates integrin-linked kinase (ILK), thereby negatively regulating ILK kinase activity. This dephosphorylation event modulates a signaling axis encompassing AKT, GSK3??, and ??-catenin, positioning ILKAP as a critical node in integrin-mediated signal transduction. Upstream, ILKAP activity is influenced by integrin engagement, transforming growth factor-?? (TGF-??), and interactions with extracellular matrix components. Within the focal adhesion complex, ILKAP forms part of a macromolecular assembly including ILK, PINCH, and parvin, while its downstream effects converge on key pathways such as PI3K/AKT signaling and the Wnt/??-catenin cascade, impacting cell adhesion, migration, and transcriptional programs.
In the A-549 lung adenocarcinoma background, disruption of ILKAP expression is particularly significant for dissecting the molecular underpinnings of tumor progression and metastasis. The ILKAP phosphatase is thought to counteract oncogenic signaling driven by hyperactive ILK and AKT, which are frequently dysregulated in lung cancers. Thus, this knockout model enables direct interrogation of how loss of ILKAP-mediated dephosphorylation alters cell adhesion dynamics, migration capacity, and invasive potential in an epithelial lung carcinoma context. It provides a controlled genetic system to evaluate the contribution of ILKAP to tumor suppression or, conversely, to identify compensatory signaling mechanisms that emerge upon its inactivation, offering insight into lung adenocarcinoma pathophysiology.
This polyclonal knockout cell population is ideally suited for a range of experimental applications, including functional dissection of ILKAP-dependent signaling, mechanistic studies of integrin?Cfocal adhesion biology, and preclinical drug target validation. Researchers can employ Western blotting to assess changes in phosphorylated ILK, AKT, GSK3??, and ??-catenin, co-immunoprecipitation to probe ILKAP?CILK complex formation, and cell migration or invasion assays under various stimuli. Immunofluorescence visualization of focal adhesion structures and RT-qPCR profiling of Wnt/??-catenin target genes further expand analytical possibilities. The model also supports phospho-signaling array analyses and high-content screening for modulators of phosphatase activity. For further technical information or to inquire about custom modifications, please contact Ascent Research.
